Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Generic diabetes drug put to the test against Brand-Name synjardy XR

NCT ID NCT07266766

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study checks whether a generic version of the diabetes drug empagliflozin/metformin works the same as the brand-name Synjardy XR. Forty healthy adults each take one dose of both pills under fed conditions, and researchers compare how much drug gets into the bloodstream. The goal is to see if the generic is a suitable, lower-cost alternative.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
empagliflozin and metformin extended-release tablets
What this could lead to
If successful, this could help bring a more affordable generic version of this diabetes medication to market.
What could go wrong
This is an early-phase bioequivalence study in only 40 healthy people, not patients. It does not test whether the drug works for diabetes, only that the generic matches the brand in absorption.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

40 people

The number who actually took part.

Started

Aug 2025

Finished

Oct 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 45 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Subjects aged between 18 to 45 years (both inclusive). * Subjects' weight within normal range according to normal values for Body Mass Index (between 18.5 to 30.0 kg/m2) (both inclusive) with minimum of 45 kg weight. * Subjects with normal health as determined by personal medical history, clinical examination and laboratory examinations within Predefined site Normal range. * Subjects having clinically acceptable 12-lead electrocardiogram (ECG). * Subjects having clinically acceptable chest X-Ray (PA view), if taken. * Subjects having negative urine screen for drugs of abuse (including amphetamines, barbiturates, benzodiazepines, marijuana, cocaine, and morphine). * Subjects having negative urine alcohol test / breath alcohol test. * Non-smoker. * Subjects willing to adhere to the protocol requirements and to provide written informed consent. * Subject with Creatinine Clearance ˃60 ml/min. * For male Subjects: Subjects willing to follow approved birth control methods (a double barrier method) for the duration of the study as judged by the investigator(s), such as (a double barrier method) condom with spermicide, Condom with diaphragm, or abstinence. Subjects willing to refrain from donating sperm during the study period - For Female Subjects: Female of child bearing potential practicing an acceptable method of birth control for the duration of the study as judged by the investigator(s), such as intrauterine device (IUD), abstinence, bilateral tubal ligation or double barrier contraception, i.e., condom + diaphragm, condom + spermicidal or foam Postmenopausal for at least 1 year, or if less than 1 year, then following acceptable contraceptive measures as mentioned above \- Subjects having negative urine pregnancy test at screening and negative serum b-hCG pregnancy test on admission day of period 01 (only for female subjects). Exclusion Criteria: * Hypersensitivity to Empagliflozin and Metformin or related class of drugs or any of its excipients or heparin. * History or presence of significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, endocrine, immunological, dermatological, neurological, urogenital or psychiatric disease or disorder. * Any treatment which could bring about induction or inhibition of hepatic microsomal enzyme system within 30 days prior to admission in period 01. * Presence of alcoholism or drug abuse. * History or presence of asthma, urticaria or other significant allergic reactions. * History or presence of significant gastric and/or duodenal ulceration. * History or presence of significant thyroid disease, adrenal dysfunction, organic intracranial lesion such as pituitary tumor. * History or presence of cancer or basal or squamous cell carcinoma. * Difficulty with donating blood. * Difficulty in swallowing solids dosage form like tablets or capsules. * Use of any prescribed medication or OTC medication including vaccines, vitamins and herbal remedies during last 30 days prior to admission in period 01. * Major illness within past 3 months. * Volunteer who have donated blood (1 unit) or participation in a drug research study within past 90 days prior to the first dose of the study drug. * Consumption of xanthine-containing products, tobacco containing products or alcohol or any alcohol containing products within 48.00 hours prior to admission in period 01. * Consumption of grapefruit or grapefruit juice containing products within 72.00 hours prior to admission of period 01. * Positive screening test for any one or more: HIV, Hepatitis B and Hepatitis C. * History or presence of significant easy bruising or bleeding. * History or presence of significant recent trauma. * Subjects who have been on an abnormal diet (for whatever reason) during the four weeks preceding the study. * History of any type of acute metabolic acidosis (such as lactic acidosis, diabetic ketoacidosis). * History of Diabetic pre-coma. * History of acute conditions with the potential to alter renal function such as: dehydration, severe infection, shock. * History of disease which may cause tissue hypoxia (especially acute disease, or worsening of chronic disease) such as: decompensated heart failure, respiratory failure, recent myocardial infarction, shock. * History of Hepatic impairment or acute alcohol intoxication. * Female subjects who are currently breast feeding.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Type 2 diabetes mellitus (T2DM) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Veeda Clinical Research Limited

    Ahmedabad, Gujarat, 384205, India

More trials for these conditions

Other studies related to the condition(s) this trial covers.